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Background: Chemo-radiation is considered to be the standard treat-
ment for the management of limited disease of small cell lung cancer
(SCLC). Even in this early stage, the role of surgery in SCLC is still
controversial. We sought to examine the role of surgery; complete
resection in terms of survival in SCLC. Method: A retrospective review
was undertaken of patients who underwent surgery for SCLC between
2001 and 2015. Patients were staged according to the 7th edition of the
Tumor, Node, Metastasis classification of lung cancer. Actuarial survival
estimatedwith KaplanMeiermethod and comparisons were undertaken
using Cox regression hazard model. Clinicopathological factors and
predictors of survival were analyzed. Result: We identified 49 patients
who underwent complete resection. The mean follow up period was
1343 days. The mean age was 70.7 years. 40 patients were men and 9
were women. The number of patients of clinical stage was stage IA :21,
IB: 15, IIA: 4, IIB: 6, IIIA:3. Operative procedure was lobectomy in 43,
segmentectomy in 1, wedge resection in 5. The number of patients of
pathological stage was stage IA :15, IB: 11, IIA: 14, IIB: 7, IIIA:2. Adjuvant
chemotherapy was performed in 26 patients (53.1%). The 5-year overall
survival (OS) rate in all patients was 58.8%. The 5-year OS was 61.3% in
c-stage I, 54.5% in c-stage II, and 50% in c-stage III. The 5-year OS were
66.2% in p-stage I, 55.4% in p-stage II, and 50% in p-stage III. The 5-year
OS of patients with adjuvant chemotherapy was significantly better than
that of patients without adjuvant chemotherapy (77.8% vs. 39.8%,
p¼0.005). Multivariable Cox regression hazard model demonstrated
that adjuvant chemotherapy was prognostic factor of overall survival
(OS) (hazard ratio 0.255 (.095-.688), p¼0.007) Conclusion: Surgical
outcome for early stage SCLC was satisfied one. The role of surgery for
this group seemed to be important. Adjuvant chemotherapy may
improve prognosis and long-term survival will be expected. Keywords:
chemotherapy, small cell lung cancer, Surgery
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Background: The combination chemotherapy of etoposide and a
platinum salt represents the standard therapy for almost 30 years in
patients with ED-SCLC (extensive-disease small-cell lung cancer).
While, the survival benefit of chemotherapy is not obvious. Anti-
angiogenic agents have been confirmed to have survival benefits for
patients with NSCLC (non-small cell lung cancer). However, there is no
established role for antiangiogenic therapy in SCLC. Method: we con-
ducted this meta-analysis to evaluate antiangiogenic agents plus
chemotherapy in patients with ED-SCLC. Pub-med, EMBASE, Cochrane
Library and ClinicalTrials.gov website were systematically searched for
RCTs (randomized controlled trials) that compared antiangiogenic
agents plus chemotherapy with chemotherapy alone in ED-SCLC.
Result: We firstly found that antiangiogenic agents plus chemotherapy
was well tolerated and could provide a statistically significant
improvement in PFS (progression-free survival) for patients withED-SCLC (HR ¼ 0.76 [95% CI 0.65, 0.88], P ¼ 0.0003). The results of
ORR (objective response rate) (RR ¼ 1.06 [95% CI 0.96, 1.18], P ¼
0.23) and OS (overall survival) (HR ¼ 0.98 [95% CI 0.80, 1.21], P ¼
0.85) showed no benefit for antiangiogenic agents plus chemotherapy.
Conclusion: Our study firstly shows that the addition of antiangiogenic
agents to standard chemotherapy is well tolerated and can provide a
statistically significant improvement in PFS for patients with ED-SCLC.
Further, maintenance therapy with antiangiogenic agents is an effective
treatment option for ED-SCLC patients who received four to six cycle of
chemotherapy. Additionally, four-drug chemotherapy plus anti-
angiogenic agents may be better for ED-SCLC patients with PS of 1 to 2.
However, whether antiangiogenic agents plus chemotherapy can in-
fluence OS for ED-SCLC needs further validation. Keywords: small cell
lung cancer, chemotherapy, antiangiogenic agents
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Background: Patients with epidermal growth factor receptor (EGFR)
mutant advanced non-small cell lung cancer (NSCLC) developed resis-
tance to first- or second-generation EGFR-tyrosine kinase inhibitor (TKI)
after 9-13 months and third-generation EGFR-TKI after 10 months,
respectively. Small cell lung cancer (SCLC) transformation is a rare
resistance mechanism in these patients. Method: Tissue re-biopsy was
performed in 35 patients with EGFR mutant advanced NSCLC who failed
first-line EGFR-TKI; and 4 patients with acquired T790Mmutant advanced
NSCLC who failed third-generation EGFR-TKI, to look for SCLC trans-
formation Result: SCLC transformation was identified in 2 out of 35
(5.7%) patients who failed first-line EGFR-TKI and 1 out of 4 (25.0%)
patients who failed third-generation EGFR-TKI. The first patient was a 70-
year-old never-smoker male who was diagnosed with stage IV lung
adenocarcinoma harboring exon 19 deletion mutation in April 2014. He
had partial response (PR) to gefitinib 250 mg daily but developed
symptomatic progressive disease (PD) after 26 months. Re-biopsy of his
enlarging primary lung lesion showed SCLC transformation. The second
patient was a 43-year-old never-smoker male who was diagnosed with
stage IV lung adenocarcinoma harboring exon 19 deletion mutation in
November 2015. He had PR to gefitinib 250 mg daily but developed
symptomatic PD after 15 months. Re-biopsy of his rapidly enlarging pri-
mary lung lesion showed SCLC transformation. His plasma cell-free tumor
DNA (cftDNA) was positive for T790M mutation. The third patient was a
62-year-old never-smoker female who was diagnosed with stage IV lung
adenocarcinoma harboring exon 21 L858R mutation in November 2015.
She had PR to gefitinib 250 mg daily but experienced symptomatic PD
after 8 months’ of gefitinib therapy. Re-biopsy of her primary lung tumor
revealed the presence of T790M mutation and her treatment was
switched to osimertinib 80 mg daily. After an initial PR, she developed PR
in the 12th month of osimertinib treatment. Biopsy from a metastatic
inguinal lymph node showed SCLC. The first and second patients were
given standard SCLC chemotherapy with carboplatin and etoposide but
did not respond. The third patient sought treatment in another hospital.
Conclusion: Re-biopsy is recommended in all patients with symptomatic
PD while on EGFR-TKI treatment. SCLC transformation under the pressure
of first, second and third-generation EGFR-TKI is an emerging challenge to
the management of advanced NSCLC. Other than conventional carboplatin
and etoposide chemotherapy, new treatment strategies should be
explored to improve the outcome of patients who develop SCLC trans-
formation. Keywords: Epidermal growth factor receptor, resistance
mechanism, small cell lung cancer
